Skip to main content
Clinical Trials/NCT04963972
NCT04963972
Unknown
Not Applicable

Impact of Digital and Behavioral Tele-Health Tapering Program for Perioperative Surgical Patients Exposed to Opioids

Lucid Lane, Inc1 site in 1 country272 target enrollmentFebruary 23, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Malignant Abdominal Neoplasm
Sponsor
Lucid Lane, Inc
Enrollment
272
Locations
1
Primary Endpoint
Percent tapered off of opioid in the telehealth group over time compared to usual care (opioid naive)
Last Updated
3 years ago

Overview

Brief Summary

This clinical trial studies the effect of behavioral health support including tele-health in helping surgical patients taper off of prescription opioid pain medications. "Tapering off" means taking dose amounts of medication that get smaller over time, so that less and less of the drug is used until it is not needed anymore. Researchers want to learn how these techniques may improve a patient's ability to lower or avoid dependence on opioid medications after surgery, and if behavioral therapies may improve quality of life, emotional well-being, and functional status around surgery.

Detailed Description

PRIMARY OBJECTIVE: I. To evaluate the impact of Lucid Lane's perioperative opioid tapering program utilizing daily behavioral health support (Health Insurance Portability and Accountability Act \[HIPAA\]-compliant sessions of cognitive behavioral therapy \[CBT\], mindfulness, 1:1 psychotherapy, group therapy, and 2-way texting and chat, all interactions with Lucid Lane licensed therapists), for patients who are on an opioid medication prior to surgery (tolerant), or naive and will be undergoing a surgery with curative intent post-surgery. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients participate in the Lucid Lane therapy program including working with a mental health therapist on mindfulness, CBT, group therapy, and mind-body therapies for 3-9 months or until the tapering off period is complete. ARM II: Patients receive standard of care post-surgical opioid education.

Registry
clinicaltrials.gov
Start Date
February 23, 2021
End Date
February 1, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Lucid Lane, Inc
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Greater than or equal to 18 years of age
  • Patients undergoing head and neck cancer surgery, open abdominal surgery, thoracic surgery
  • Life-expectancy of 270 days or more
  • Patients who will receive opioids as part of their treatment post-operatively
  • Perioperative opioid use:
  • Naive Arm: No opioids 30 days prior to surgery
  • Tolerant Arm: Use of opioids on 2 or more days/week, for 1 or more months prior to surgery
  • Patient is willing to use Lucid Lane program to provide behavioral health support perioperative period up to 9 months post-op for tolerant opioid users and 1 month for opioid naive users
  • Patient is willing to discuss Lucid Lane progress with MD Anderson perioperative team and prescribing clinicians
  • Patient is willing to sign a Lucid Lane Participant Agreement

Exclusion Criteria

  • Serious mental illnesses including schizophrenia-spectrum disorders, severe bipolar disorder, and severe major depression
  • Active suicidal ideations
  • Patients on methadone, naltrexone, or buprenorphine for treatment of opioid use disorder (i.e. for treatment of addiction, and not for treatment of pain)
  • Patient unwilling to use or not possessing access to a device that allows for video visits (e.g. a smartphone, tablet, or computer)
  • Patients who are on end-of-life care
  • Insufficient ability to use English to participate in the consent process, the intervention or study assessments. The Lucid Lane therapists will be conducting therapy sessions in English, and the ability to understand English is required for the consent process. All questionnaires and surveys will be in English to ensure appropriate and comprehensive care for this patient population
  • Insufficient ability to provide informed consent to participate

Outcomes

Primary Outcomes

Percent tapered off of opioid in the telehealth group over time compared to usual care (opioid naive)

Time Frame: Up to 90 days

Percent tapered off of opioid in the telehealth group over time compared to usual care (opioid tolerant)

Time Frame: Up to 270 days

Secondary Outcomes

  • Change in quality of life measures between telehealth group and usual care(Baseline up to 9 months)
  • Change in emotional well-being (EWB) between telehealth group and usual care(Baseline up to 9 months)
  • Change in pain assessment between telehealth group and usual care(Baseline up to 9 months)
  • Change in satisfaction between telehealth group and usual care(Baseline up to 9 months)
  • Incidence of adverse events(Up to 9 months)

Study Sites (1)

Loading locations...

Similar Trials